Search clinical trials for: gefitinib

Total 384 results

Fondazione Humanitas per la Ricerca

Completed

Randomized Gefitinib Trial (RANGE)

Non Small Cell Lung Cancer

Italy
St. Jude Children's Research Hospital
AstraZeneca

Completed

ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors

Glioblastoma | Osteosarcoma | Neuroblastoma | Rhabdomyosarcomas

United States
National University Hospital, Singapore
National Healthcare Group, Singapore

Completed

A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839

Nasopharyngeal Carcinoma

Singapore
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States
Benaroya Research Institute
Sanofi; AstraZeneca

Completed

Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer

Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Completed

Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas

Gastric Cancer | Esophageal Cancer

United States, Puerto Rico
Seoul Veterans Hospital

Unknown

Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy (SIIS)

Squamous Cell Carcinoma of Bronchus

Korea, Republic of
Groupe Oncologie Radiotherapie Tete et Cou
AstraZeneca

Terminated

Post-operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract Carcinomas

Head and Neck Cancer

France
AstraZeneca

Completed

Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)

Non-Small Cell Lung Cancer

Netherlands
Pfizer

Completed

Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma

Carcinoma, Renal Cell

United States
ZhuGuangYing
Zhejiang Cancer Hospital; 307 Hospital of PLA; Fudan University; Cancer Institute... and other collaborators

Unknown

Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
AstraZeneca

Terminated

Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

Non Small Cell Lung Carcinoma

Italy
AstraZeneca

Completed

Iressa Versus Docetaxel (Taxotere)

Non-Small-Cell Lung Carcinoma

United States, Croatia, Sweden, Italy, Mexico, Spain, Turkey, Germany, Philippines, Malaysia, China, Estonia, Latvia, Hong Kong, Argentina, Belgium, Canada, Denmark, France, Indonesia, Thailand, Brazil, Switzerland, Singapore, Slovenia
SCRI Development Innovations, LLC
AstraZeneca

Completed

Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer

Lung Cancer
Samsung Medical Center

Unknown

Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)

Nonsmall Cell Lung Cancer

Korea, Republic of
Zhejiang Cancer Hospital

Unknown

Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer

Esophageal Cancer

China
AstraZeneca

Withdrawn

A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer

Breast Cancer

Italy
AstraZeneca

Withdrawn

Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Italy
AstraZeneca

Completed

ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer

Head and Neck Cancer

Spain
AstraZeneca

Completed

Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer

Breast Cancer

Sweden, Norway, Denmark
AstraZeneca

Completed

Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

Squamous Cell Carcinoma of the Head and Neck

Croatia, Sweden, United States, Czech Republic, Italy, Russian Federation, South Africa, Spain, United Kingdom, Estonia, Latvia, Lithuania, Norway, Canada, Netherlands, Argentina, Belgium, Greece, Thailand, India, Israel, Malaysia, ... and more
AstraZeneca

Withdrawn

Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer | Carcinoma, Squamous Cell

Italy
AstraZeneca

Completed

Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer

Locally Advanced Prostate Cancer

Norway
AstraZeneca

Completed

A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer

Non-small-cell Lung Cancer

United Kingdom
AstraZeneca

Completed

A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme

Glioblastoma

Sweden
National Cancer Center, Korea
AstraZeneca

Completed

First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker

Lung Cancer

Korea, Republic of
AstraZeneca

Completed

Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand

Lung Cancer

Thailand
AstraZeneca

Completed

Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer (IRESSA&H&N)

Head and Neck Cancer

Switzerland
Eli Lilly and Company

Completed

Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers

Non-small Cell Lung Cancer

China, Korea, Republic of, Taiwan
Fudan University

Unknown

Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients

Non-small Cell Lung Cancer | Toxicity

China
AGO Study Group

Completed

A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy

Ovarian Cancer | Peritoneal Cancer | Cancer of the Fallopian Tube

Germany
Zhejiang Cancer Hospital

Unknown

Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)

Non-small Cell Lung Cancer

China
AstraZeneca

Completed

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

Pulmonary Cancer

Korea, Republic of
SCRI Development Innovations, LLC
AstraZeneca; Aventis Pharmaceuticals

Completed

Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer

Head and Neck Cancer

United States
AstraZeneca

Completed

A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa

Non-small Cell Lung Cancer

China
Intergroupe Francophone de Cancerologie Thoracique
Sanofi; AstraZeneca

Completed

Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV

Carcinoma, Non-Small-Cell Lung

France
Stanford University
AstraZeneca; American Society of Clinical Oncology

Completed

Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck

Head and Neck Cancer | Carcinoma, Squamous Cell

United States
Samsung Medical Center

Unknown

Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Non-small Cell Lung Cancer

Korea, Republic of
Taipei Veterans General Hospital, Taiwan

Completed

UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer

Non-Small-Cell Lung Cancer

Taiwan
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham...

Completed

Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer

Metastatic Pancreatic Carcinoma

United States
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI); Norris Cotton Cancer Center

Completed

Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer

Breast Cancer

United States
AstraZeneca

Completed

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

Neoplasms, Squamous Cell

United States, Czech Republic, Poland, Germany, Belgium, Taiwan, India, Serbia
AstraZeneca

Completed

Phase II Iressa & Carbo/Gem in NSCLC

Carcinoma, Non-Small-Cell Lung

Canada
AstraZeneca

Terminated

Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer

Brain Neoplasms | Non Small Cell Lung Cancer

Italy
AstraZeneca

Completed

Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

Advanced Tumor

Netherlands
AstraZeneca

Completed

IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma

Cancer of Head and Neck

Spain
AstraZeneca

Completed

Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study

Breast Cancer

Sweden, Czech Republic, France, Spain, United Kingdom, Hungary, Portugal
AstraZeneca
Cancer International Research Group (CIRG)

Completed

Ph II Early BC Pre-Surgical Biologic Study

Breast Cancer
AstraZeneca

Completed

Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer

Non-Metastatic Prostate Cancer

Finland
AstraZeneca

Completed

Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy

Prostate Cancer

Finland

3

Subscribe